Repurposing Inhaled Ibuprofenate, a Non Steroidal Anti‐Inflammatory Drug, as a Potential Adjuvant Treatment for Pneumonia, CARDS and its Aetiological Agent SARS‐CoV‐2

In this manuscript, we will describe and highlight the most important potential underlying mechanisms of action inhaled sodium ibuprofenate in hypertonic saline formulation-NaIHS aerosolisable, as a probable adjuvant treatment for moderate severe pneumonia coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome COVID-19. both pathological entities, refer exclusively to pulmonary vasoplegic type following therapeutic effects NaIHS: anti-inflammatory, immunomodulatory antiangiogenic. The synergistic these anti-inflammatory together may exert their at level through possible reversal vasoplegia thereby restore hypoxic vasoconstriction, correcting uncoupling ventilation/perfusion ratio intrapulmonary shunting and, above all, it reverse hypoxaemia failure. We also mention virucidal NaIHS on syndrome-coronavirus 2 (SARS-CoV-2). There are available three retrospective observational studies COVID-19 pneumonia, carried out Argentina, with all concluding that there was significant reduction mortality. conducted approval Institutional Review Board National Bureau Economic Research Harvard Columbia Universities, which analysed data from 5146 patients concluded reduced mortality by 48.7%, although randomized clinical trials still needed confirm emerging enable rise new treatment. Conclusively, deem essential reuse known drugs, such ibuprofen, COVID-19, due constant emergence variants subvariants concern secondary mutations immune escape (SARS-CoV-2), since effective medical treatments currently scarce many them controversial or not worldwide.